CN109750001A - 一种来源于脊柱的人原代骨肉瘤细胞株NEO217-luc及其构建方法和应用 - Google Patents
一种来源于脊柱的人原代骨肉瘤细胞株NEO217-luc及其构建方法和应用 Download PDFInfo
- Publication number
- CN109750001A CN109750001A CN201811601277.4A CN201811601277A CN109750001A CN 109750001 A CN109750001 A CN 109750001A CN 201811601277 A CN201811601277 A CN 201811601277A CN 109750001 A CN109750001 A CN 109750001A
- Authority
- CN
- China
- Prior art keywords
- cell
- osteosarcoma
- neo217
- luc
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000008968 osteosarcoma Diseases 0.000 title claims abstract description 83
- 238000010276 construction Methods 0.000 title claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 147
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 16
- 238000005119 centrifugation Methods 0.000 claims description 14
- 108060001084 Luciferase Proteins 0.000 claims description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 229930182555 Penicillin Natural products 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 8
- 229940049954 penicillin Drugs 0.000 claims description 8
- 239000005089 Luciferase Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 239000012894 fetal calf serum Substances 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 230000010355 oscillation Effects 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 229920001917 Ficoll Polymers 0.000 claims description 3
- 108010019160 Pancreatin Proteins 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 238000005138 cryopreservation Methods 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229940055695 pancreatin Drugs 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000013611 chromosomal DNA Substances 0.000 claims description 2
- 238000011010 flushing procedure Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000007920 subcutaneous administration Methods 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 5
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 230000002950 deficient Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000005740 tumor formation Effects 0.000 abstract description 4
- 238000011337 individualized treatment Methods 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000000877 morphologic effect Effects 0.000 abstract description 2
- 239000013612 plasmid Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 210000002303 tibia Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 101100520452 Arabidopsis thaliana PMD2 gene Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KEYDJKSQFDUAGF-YIRKRNQHSA-N prostaglandin D2 ethanolamide Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(=O)NCCO)[C@@H](O)CC1=O KEYDJKSQFDUAGF-YIRKRNQHSA-N 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811601277.4A CN109750001A (zh) | 2018-12-26 | 2018-12-26 | 一种来源于脊柱的人原代骨肉瘤细胞株NEO217-luc及其构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811601277.4A CN109750001A (zh) | 2018-12-26 | 2018-12-26 | 一种来源于脊柱的人原代骨肉瘤细胞株NEO217-luc及其构建方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109750001A true CN109750001A (zh) | 2019-05-14 |
Family
ID=66403149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811601277.4A Pending CN109750001A (zh) | 2018-12-26 | 2018-12-26 | 一种来源于脊柱的人原代骨肉瘤细胞株NEO217-luc及其构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109750001A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112080473A (zh) * | 2020-09-16 | 2020-12-15 | 中山大学附属第一医院 | 骨肉瘤肺部转移灶原代细胞株及其培养方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003792A (zh) * | 2006-01-16 | 2007-07-25 | 中国人民解放军军事医学科学院野战输血研究所 | 稳定表达萤火虫荧光素酶的9lluc细胞株的构建与应用 |
CN101453961A (zh) * | 2006-05-08 | 2009-06-10 | 纽瓦西弗公司 | 胶原酶处理的并且基本上不含血细胞的松质骨 |
CN102154209A (zh) * | 2010-02-12 | 2011-08-17 | 姚阳 | 一种人骨肉瘤细胞株及其应用 |
CN108464984A (zh) * | 2018-04-09 | 2018-08-31 | 徐州维康生物科技有限公司 | 一种治疗骨肉瘤的表观遗传药物 |
-
2018
- 2018-12-26 CN CN201811601277.4A patent/CN109750001A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003792A (zh) * | 2006-01-16 | 2007-07-25 | 中国人民解放军军事医学科学院野战输血研究所 | 稳定表达萤火虫荧光素酶的9lluc细胞株的构建与应用 |
CN101453961A (zh) * | 2006-05-08 | 2009-06-10 | 纽瓦西弗公司 | 胶原酶处理的并且基本上不含血细胞的松质骨 |
CN102154209A (zh) * | 2010-02-12 | 2011-08-17 | 姚阳 | 一种人骨肉瘤细胞株及其应用 |
CN108464984A (zh) * | 2018-04-09 | 2018-08-31 | 徐州维康生物科技有限公司 | 一种治疗骨肉瘤的表观遗传药物 |
Non-Patent Citations (1)
Title |
---|
ZHENHUA ZHOU 等: "Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine", 《RESEARCH DATA POLICY AND DATA AVAILABILITY STATEMENTS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112080473A (zh) * | 2020-09-16 | 2020-12-15 | 中山大学附属第一医院 | 骨肉瘤肺部转移灶原代细胞株及其培养方法和应用 |
CN112080473B (zh) * | 2020-09-16 | 2022-06-03 | 中山大学附属第一医院 | 骨肉瘤肺部转移灶原代细胞株及其培养方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103627673B (zh) | 一种人脑胶质瘤细胞系及其建立方法和应用 | |
CN103667176B (zh) | 鲤疱疹病毒ⅱ型敏感的异育银鲫脑组织细胞系及其建立方法和应用 | |
CN110475860A (zh) | 使用肿瘤组织的原代癌细胞的三维培养 | |
CN102250840B (zh) | 一种人胰腺癌细胞系及其应用 | |
CN102115730A (zh) | 稳定指示自噬的高转移潜能肝癌细胞株及其建立和应用方法 | |
CN104531620A (zh) | 肺癌干细胞条件3d培养方法 | |
CN104651302A (zh) | 一种骨髓单核细胞提取及向破骨细胞分化的方法 | |
CN106367393B (zh) | 小鼠前列腺癌循环肿瘤细胞系及前列腺癌循环肿瘤细胞分离和培养方法 | |
CN102719403B (zh) | 一种人胰腺腺鳞癌细胞系及其建立方法和应用 | |
CN102329775B (zh) | 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 | |
CN108866000A (zh) | 一种人表皮生长因子酪氨酸激酶抑制剂获得性耐药肺癌细胞系及其建立方法和应用 | |
CN109750001A (zh) | 一种来源于脊柱的人原代骨肉瘤细胞株NEO217-luc及其构建方法和应用 | |
CN109402175A (zh) | 表达趋化因子受体ccr2b的脂肪干细胞及制备方法与应用 | |
CN111363721B (zh) | 一种多西他赛诱导建立的luminal型乳腺癌多药耐药细胞株及其构建方法和应用 | |
CN110499290B (zh) | 一株人尤文肉瘤细胞系 | |
CN107227296A (zh) | 一种骨髓单核细胞分离、鉴定及诱导分化的方法 | |
US20130196349A1 (en) | In Vitro Tumor Metastasis Model | |
CN106834232A (zh) | 人垂体腺瘤细胞系及其用途 | |
CN102424817B (zh) | 一种来源于人肺腺癌的细胞株及其制备方法 | |
CN105400879B (zh) | lncRNAs筛选方法、ADSCs、软骨细胞诱导分化方法 | |
CN105219732B (zh) | 一种永生化人肝癌血管内皮细胞系及其制备方法和应用 | |
CN109749998A (zh) | 一种人原代骨巨细胞瘤细胞株GCTB28-luc及其构建方法和应用 | |
CN109073626A (zh) | 使用细胞增殖法的循环肿瘤细胞的检测·分离获取方法 | |
CN111662874A (zh) | 一种中国人食管鳞癌细胞系及其应用 | |
CN102424816A (zh) | 一种来源于人小细胞肺癌放化疗后复发病灶的细胞株及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhou Zhenhua Inventor after: Cao Jiashi Inventor after: Xiao Jianru Inventor after: Hu Shuo Inventor after: Wang Xudong Inventor after: Zhang Weiwei Inventor after: Kuang Muyu Inventor after: Gong Dejun Inventor after: Jia Qi Inventor after: Li Yan Inventor before: Zhou Zhenhua Inventor before: Cao Jiashi Inventor before: Xiao Jianru Inventor before: Hu Shuo Inventor before: Wang Xudong Inventor before: Zhang Weiwei Inventor before: Kuang Muyu Inventor before: Gong Dejun Inventor before: Jia Qi Inventor before: Li Yan |
|
CB03 | Change of inventor or designer information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190514 |
|
RJ01 | Rejection of invention patent application after publication |